The Company has received support from the Regional Research Council to perform studies on mouse models of dementia and Down syndrome in collaboration with Professor. Linda Hildegaard Bergersen at the University of Oslo, Norway. These studies will define the dose of the novel DYRK1A inhibitor development candidate PST-674, that will enter into formal toxicology and safety studies.